Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies

John F. Greden; Sagar V. Parikh; Anthony J. Rothschild; Michael E. Thase; Boadie W. Dunlop; Charles DeBattista; Charles R. Conway; Brent P. Forester; Francis M. Mondimore; Richard C. Shelton; Matthew Macaluso; James Li; Krystal Brown; Alexa Gilbert; Lindsey Burns; Michael R. Jablonski; Bryan Dechairo

doi:10.1016/j.jpsychires.2019.04.027

Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies

John F. Greden, Sagar V. Parikh, Anthony J. Rothschild, Michael E. Thase, Boadie W. Dunlop, Charles DeBattista, Charles R. Conway, Brent P. Forester, Francis M. Mondimore, Richard C. Shelton, Matthew Macaluso, James Li, Krystal Brown, Alexa Gilbert, Lindsey Burns, Michael R. Jablonski, Bryan Dechairo

School of Medicine

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	211-213
Number of pages	3
Journal	Journal of Psychiatric Research
Volume	114
DOIs	https://doi.org/10.1016/j.jpsychires.2019.04.027
State	Published - Jul 2019

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/j.jpsychires.2019.04.027

Cite this

Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, K., Gilbert, A., Burns, L., Jablonski, M. R., & Dechairo, B. (2019). Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies. Journal of Psychiatric Research, 114, 211-213. https://doi.org/10.1016/j.jpsychires.2019.04.027

Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies. / Greden, John F.; Parikh, Sagar V.; Rothschild, Anthony J. et al.
In: Journal of Psychiatric Research, Vol. 114, 07.2019, p. 211-213.

Research output: Contribution to journal › Letter › peer-review

Greden, JF, Parikh, SV, Rothschild, AJ, Thase, ME, Dunlop, BW, DeBattista, C, Conway, CR, Forester, BP, Mondimore, FM, Shelton, RC, Macaluso, M, Li, J, Brown, K, Gilbert, A, Burns, L, Jablonski, MR & Dechairo, B 2019, 'Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies', Journal of Psychiatric Research, vol. 114, pp. 211-213. https://doi.org/10.1016/j.jpsychires.2019.04.027

Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C et al. Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies. Journal of Psychiatric Research. 2019 Jul;114:211-213. doi: 10.1016/j.jpsychires.2019.04.027

@article{465e54255ed34ac68acf6699a24d2eda,

title = "Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies",

author = "Greden, {John F.} and Parikh, {Sagar V.} and Rothschild, {Anthony J.} and Thase, {Michael E.} and Dunlop, {Boadie W.} and Charles DeBattista and Conway, {Charles R.} and Forester, {Brent P.} and Mondimore, {Francis M.} and Shelton, {Richard C.} and Matthew Macaluso and James Li and Krystal Brown and Alexa Gilbert and Lindsey Burns and Jablonski, {Michael R.} and Bryan Dechairo",

note = "Funding Information: Brent P Forester : Research funding: the National Institutes of Health , Rogers Family Foundation , Assurex Health , Eli Lilly , Biogen , and Roche; Consultant: Eli Lilly and INSYS Therapeutics. Funding Information: Sagar Parikh: Research funding: the Ontario Brain Institute, the Canadian Institutes of Health Research, the James and Ethel Flinn Foundation; Paid consultant: Assurex Health; Honoraria: Mensante Corporation, Takeda, and the Canadian Network for Mood and Anxiety Treatments (CANMAT); Equity: Mensante.Anthony J Rothschild: Research support: Allergan, AssureRx, Janssen, the National Institute of Mental Health, Takeda, Eli-Lilly, and Pfizer; Consultant: Alkermes, Eli Lilly and Company, GlaxoSmithKline, Myriad Genetics, Pfizer, Sage Therapeutics, and Sanofi-Aventis; Royalties from Rothschild Scale for Antidepressant Tachyphylaxis (RSAT){\textregistered}; Clinical Manual for the Diagnosis and Treatment of Psychotic Depression, American Psychiatric Press, 2009; The Evidence-Based Guide to Antipsychotic Medications, American Psychiatric Press, 2010; The Evidence-Based Guide to Antidepressant Medications, American Psychiatric Press, 2012, and UpToDate{\textregistered}.Michale Thase: Research support: Assurex Health, Acadia, Agency for Healthcare Research and Quality, Alkermes, Avanir, Forest, Intracellular, Janssen, National Institute of Mental Health, Otsuka, Patient-Centered Outcomes Research Institute, Takeda; Consultant: Acadia, Akilii, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer, Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Merck, Moksha8, Nestl{\'e} (PamLab), Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda; Royalties from American Psychiatric Press, Guilford Publications, Herald House, W.W. Norton & Company, Inc.Boadie W Dunlop: Research support: Acadia, Assurex Health, Axsome, Janssen, and Takeda; Consultant: Assurex Health and Aptinyx.Charles DeBattista: Research support: Assurex Health and Brain Resources.Charles R Conway: Research support: LivaNova and Bristol-Myers Squibb, the Stanley Medical Research Institute, the National Institute of Mental Health, NeoSync Inc, The Taylor Family Institute for Innovative Psychiatric Research, The August Busch IV Foundation, and the Barnes-Jewish Hospital Foundation; Speaking fees: from Bristol-Myers Squibb and Otsuka Pharmaceuticals; Research design consultant: LivaNova; Part time employee: John Cochran Veterans Administration Hospital in St. Louis.Brent P Forester: Research funding: the National Institutes of Health, Rogers Family Foundation, Assurex Health, Eli Lilly, Biogen, and Roche; Consultant: Eli Lilly and INSYS Therapeutics.Francis M Mondimore: Research funding: Assurex Health.",

year = "2019",

month = jul,

doi = "10.1016/j.jpsychires.2019.04.027",

language = "English (US)",

volume = "114",

pages = "211--213",

journal = "Journal of Psychiatric Research",

issn = "0022-3956",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Response to

T2 - Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies

AU - Greden, John F.

AU - Parikh, Sagar V.

AU - Rothschild, Anthony J.

AU - Thase, Michael E.

AU - Dunlop, Boadie W.

AU - DeBattista, Charles

AU - Conway, Charles R.

AU - Forester, Brent P.

AU - Mondimore, Francis M.

AU - Shelton, Richard C.

AU - Macaluso, Matthew

AU - Li, James

AU - Brown, Krystal

AU - Gilbert, Alexa

AU - Burns, Lindsey

AU - Jablonski, Michael R.

AU - Dechairo, Bryan

N1 - Funding Information: Brent P Forester : Research funding: the National Institutes of Health , Rogers Family Foundation , Assurex Health , Eli Lilly , Biogen , and Roche; Consultant: Eli Lilly and INSYS Therapeutics. Funding Information: Sagar Parikh: Research funding: the Ontario Brain Institute, the Canadian Institutes of Health Research, the James and Ethel Flinn Foundation; Paid consultant: Assurex Health; Honoraria: Mensante Corporation, Takeda, and the Canadian Network for Mood and Anxiety Treatments (CANMAT); Equity: Mensante.Anthony J Rothschild: Research support: Allergan, AssureRx, Janssen, the National Institute of Mental Health, Takeda, Eli-Lilly, and Pfizer; Consultant: Alkermes, Eli Lilly and Company, GlaxoSmithKline, Myriad Genetics, Pfizer, Sage Therapeutics, and Sanofi-Aventis; Royalties from Rothschild Scale for Antidepressant Tachyphylaxis (RSAT)®; Clinical Manual for the Diagnosis and Treatment of Psychotic Depression, American Psychiatric Press, 2009; The Evidence-Based Guide to Antipsychotic Medications, American Psychiatric Press, 2010; The Evidence-Based Guide to Antidepressant Medications, American Psychiatric Press, 2012, and UpToDate®.Michale Thase: Research support: Assurex Health, Acadia, Agency for Healthcare Research and Quality, Alkermes, Avanir, Forest, Intracellular, Janssen, National Institute of Mental Health, Otsuka, Patient-Centered Outcomes Research Institute, Takeda; Consultant: Acadia, Akilii, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer, Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Merck, Moksha8, Nestlé (PamLab), Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda; Royalties from American Psychiatric Press, Guilford Publications, Herald House, W.W. Norton & Company, Inc.Boadie W Dunlop: Research support: Acadia, Assurex Health, Axsome, Janssen, and Takeda; Consultant: Assurex Health and Aptinyx.Charles DeBattista: Research support: Assurex Health and Brain Resources.Charles R Conway: Research support: LivaNova and Bristol-Myers Squibb, the Stanley Medical Research Institute, the National Institute of Mental Health, NeoSync Inc, The Taylor Family Institute for Innovative Psychiatric Research, The August Busch IV Foundation, and the Barnes-Jewish Hospital Foundation; Speaking fees: from Bristol-Myers Squibb and Otsuka Pharmaceuticals; Research design consultant: LivaNova; Part time employee: John Cochran Veterans Administration Hospital in St. Louis.Brent P Forester: Research funding: the National Institutes of Health, Rogers Family Foundation, Assurex Health, Eli Lilly, Biogen, and Roche; Consultant: Eli Lilly and INSYS Therapeutics.Francis M Mondimore: Research funding: Assurex Health.

PY - 2019/7

Y1 - 2019/7

UR - http://www.scopus.com/inward/record.url?scp=85066255457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066255457&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2019.04.027

DO - 10.1016/j.jpsychires.2019.04.027

M3 - Letter

C2 - 31101328

AN - SCOPUS:85066255457

SN - 0022-3956

VL - 114

SP - 211

EP - 213

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

ER -

Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this